Sinustat

Quick links to important sections

Sinustat

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinustat

Quick Facts

Property Description
Active Ingredients Acetaminophen and Phenylpropanolamine
Form Oral (Capsules, Tablets, or Syrup)
Pharmacological Class Upper Respiratory Combination
General Purpose Relief from cold-related aches, fever, and congestion
Origin Synthetic

What is Sinustat? Defining its Therapeutic Class and Type

Sinustat is a synthetic combination product classified as an Upper Respiratory Combination medication, designed to address multiple symptoms of common seasonal illnesses simultaneously. The medication's structure as a multicomponent drug defines its approach to relief, contrasting it with single-ingredient preparations. The formulation is intended for oral administration, typically available in standard forms such as capsules, tablets, or syrup. Pharmacological studies confirm that combination preparations of this type are utilized for their ability to manage the diverse symptom profile of conditions like the common cold.

Sinustat's Composition: Acetaminophen and Phenylpropanolamine

The identity of Sinustat is fundamentally defined by its two principal active ingredients [INN]: Acetaminophen (Paracetamol) and Phenylpropanolamine hydrochloride (PPA). Both components are chemically synthetic in origin. Acetaminophen contributes the recognized analgesic (pain-relieving) and antipyretic (fever-reducing) properties, while Phenylpropanolamine functions as the sympathomimetic decongestant agent. The integration of PPA is clinically recognized for its ability to target vasoconstriction in the nasal mucosa. This formula is distinct from formulations that exclusively utilize alternatives like phenylephrine for the decongestant effect.

General Purpose: Integrated Symptomatic Relief

The general purpose of Sinustat is to deliver integrated symptomatic relief by targeting both the systemic discomfort and the localized respiratory symptoms associated with upper respiratory conditions. This dual action provides a comprehensive benefit by managing generalized aches, minor pains, and fever addressed by one component, while simultaneously easing the stuffiness and pressure caused by nasal and sinus congestion due to the other. A typical use scenario involves alleviating the burden of a cold where a patient experiences both a headache and a blocked nose. The combination effect offers a broad approach to easing the overall symptom load.

What side effects are possible with Sinustat?

Possible Side Effects and Safety Information

The safety profile of Sinustat is defined by the regulatory-documented risks associated with its active components, Acetaminophen and Phenylpropanolamine, and is communicated through a focus on serious, rare, and dose-related events.

Officially Listed Adverse Reactions by System-Organ Class

Adverse effects listed in official labeling are commonly grouped by the physiological system affected. These include:

System-Organ Class (SOC) Examples of Listed Effects
Hepatobiliary Disorders Acute Liver Failure, Liver Damage
Nervous System Dizziness, Sleeplessness, Hemorrhagic Stroke
Psychiatric Disorders Nervousness, Excitability (particularly in children)
Vascular/Cardiac Increased Blood Pressure (Hypertension)
Skin & Subcutaneous Tissue Severe Skin Reactions (e.g., SJS, TEN)

Regulatory Safety Classifications and High-Risk Events

The most critical warnings mandated by regulatory authorities concern the potential for serious adverse reactions. These include:

  • Acute Liver Failure: Associated with the acetaminophen component, this risk is highest when the maximum recommended daily amount is exceeded, a factor often emphasized through a Boxed Warning.
  • Hemorrhagic Stroke: A rare, serious event linked to the phenylpropanolamine component, as noted in official government advisories.
  • Rare Skin Reactions: Life-threatening cutaneous reactions, such as Stevens-Johnson Syndrome (SJS), are officially classified as rare but required to be noted in labeling.

Population-Specific Constraints

Safety statements indicate a requirement for prior consultation or caution in certain populations. Official labeling notes that the risk of acute liver failure is documented as being higher in individuals with underlying liver disease or those who consume alcohol concurrently. Furthermore, official documents note that use requires caution for individuals with pre-existing conditions such as high blood pressure or heart disease, as these may be impacted by the decongestant component.

Exposure-Related Safety Limitations

Regulatory documentation mandates strict limitations on co-administration. It is a regulatory restriction to use Sinustat simultaneously with any other product containing acetaminophen, whether prescription or nonprescription, due to the substantial increase in the risk of hepatotoxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

The official Sinustat overdose profile is defined by two distinct, severe toxicological risks documented in regulatory sources: severe hepatic injury from the acetaminophen component and acute cardiovascular or neurological events from the Phenylpropanolamine component.

Documented Manifestations: Initial presentations may be non-specific, including nausea, vomiting, abdominal pain, pallor, or signs of CNS excitation such as restlessness, headache, and tachycardia. Delayed, life-threatening outcomes documented in regulatory sources include acute liver failure and hemorrhagic stroke or hypertensive crisis. Laboratory findings often reveal elevated serum transaminases (AST, ALT) and abnormalities in blood clotting (INR).

Mandatory Emergency Action: Regulatory documentation mandates that individuals seek immediate medical attention or contact a Poison Control Center right away, even if no symptoms are present. Immediate intervention is critical because the specific antidote, N-acetylcysteine, for the acetaminophen component is time-critical for maximal efficacy against hepatic injury. Hospital monitoring of hepatic and renal function is typically required. Increased susceptibility to toxicity is documented in populations with chronic alcoholism or pre-existing liver conditions.

Therapeutic Uses of Sinustat

What Sinustat Treats: Main Uses and Benefits

Multi-component cold relief is generally used to target various symptom types simultaneously. Sinustat is applied across domains where additional symptomatic support is needed, primarily addressing symptoms related to physical discomfort, such as generalized aches, minor pains, and headaches, and symptoms related to systemic imbalance, specifically fever. It is commonly applied in scenarios where symptoms may interfere with daily stability, providing assistance relevant for easing nasal congestion and is relevant for easing the discomfort of nasal stuffiness, sinus congestion, and pressure. The medication is relevant in conditions characterized by the integrated symptom patterns of the common cold or flu-like syndromes.

“This supportive approach assists with managing the overall symptom load and may assist with maintaining a sense of stability during difficult manifestations.”


Quick Fact: Relief for Key Symptom Domains

Symptom Domain Primary Symptom Relief Patient Benefit Focus
Systemic Discomfort Generalized aches, minor pains, fever Contributes to easing distress
Respiratory Distress Nasal stuffiness, sinus pressure Assists with maintaining functional stability
Condition Category Acute cold or flu-like syndromes Supports general well-being during symptomatic phases

Regulatory References

  1. NIH MedlinePlus overview on Cold and Cough Medicines

Eligibility and Restrictions for Use

The eligibility for Sinustat, a combination of Acetaminophen and Phenylpropanolamine (PPA), is strictly defined by regulatory warnings and contraindications related to both components.

Absolute Contraindications

The medicine must not be used by individuals with specific health conditions or drug use:

Category Regulatory Status
Cardiovascular Risk Contraindicated in patients with severe hypertension or severe coronary artery disease.
Drug Interaction Contraindicated in patients using or having recently used a Monoamine Oxidase Inhibitor (MAOI) (within 14 days).
Organ Status Contraindicated in cases of severe active liver disease or severe hepatic impairment (due to the Acetaminophen component).

Restricted and Age-Based Use

Use is not recommended or requires strict caution for other groups:

  • Pediatric Exclusion: Use is contraindicated in children younger than 2 years of age. Use in children under 12 is generally not established or recommended for these combinations.
  • Conditional Use: Individuals with conditions such as hyperthyroidism, diabetes mellitus, prostatic hypertrophy, glaucoma, or existing kidney/liver disease require caution as per official labeling.
  • Pregnancy/Lactation: Use is generally not recommended during pregnancy or while breastfeeding due to potential risks.

What should I know about interactions with other medicines?

The official interaction profile for Sinustat is defined by the distinct pharmacological properties of its two active components, Phenylpropanolamine and Acetaminophen.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the potential for severe hypertensive reactions. Regulatory documents mandate that at least 14 days must elapse after discontinuation of MAOI therapy before initiating treatment with Sinustat.

Drug-Drug Pharmacodynamic Effects

The Phenylpropanolamine component has documented additive sympathomimetic effects with other Sympathomimetics and may decrease the antihypertensive activities of certain blood pressure medications. Furthermore, an increased risk of arrhythmias is noted when co-administered with agents like Tricyclic Antidepressants, Cardiac Glycosides, or Quinidine.

Exposure Modification and Substance Restrictions

The Acetaminophen component carries a clinically significant interaction with Warfarin and other coumarins; prolonged, regular daily use is documented to enhance the anticoagulant effect and consequently increase the risk of bleeding. The interaction with chronic, excessive Alcohol consumption is classified as a risk for severe liver damage via enzyme-mediated effects. This risk is explicitly noted to be heightened in populations with hepatic impairment or active hepatic disease.

Mechanism of Action

Central Inhibition of Pyresis and Nociceptive Signaling

This domain focuses on the action of Acetaminophen, which exerts its influence primarily in the Central Nervous System (CNS) by acting as a selective inhibitor of certain Cyclooxygenase (COX) enzymes. This enzyme inhibition reduces the synthesis of the mediator Prostaglandin E2 ( PGE2), which is responsible for elevating the body's thermoregulatory set-point. By dampening this central signaling cascade, the mechanism initiates responses to adjust the thermoregulatory set-point and affects central nociceptive signaling.


Targeted Vascular Contraction in Nasal Mucosa

The decongestant component, Phenylpropanolamine, engages the Autonomic Sympathetic System peripherally by directly stimulating Alpha-1 (alpha1) Adrenergic Receptors on the blood vessels of the nasal and sinus lining. This receptor activation initiates a sequence that causes the local arterioles and venous sinuses to constrict. This physiological adjustment reduces the volume of blood pooling in the nasal tissues, which in turn reduces the volume of the mucosal tissue and limits local capillary leakage.


Complementary Regulation of Physiological Systems

The drug's overall effect profile stems from the convergence of these two mechanistically independent actions. While the Acetaminophen component modulates signaling pathways related to pyresis and nociception, the Phenylpropanolamine component physically adjusts localized vascular tone. This functional complementarity allows for the simultaneous modulation of central thermoregulatory pathways and peripheral vascular dynamics without relying on shared biological targets.

Dosage and Administration Information

Sinustat, an Upper Respiratory Combination medication, is officially administered by the oral route, typically available as a capsule, tablet, or syrup formulation. The principles of its use are governed by strict labeled instructions concerning dosage, frequency, and duration.

Official Administration and Dosing

Usage Constraint Regulatory Standard
Route of Administration Oral
Dosing Frequency Every 4 to 6 hours as required
Course Duration Limited to short-term use, often a maximum of 7 consecutive days

Standard adult unit doses of the combined active ingredients—Acetaminophen and Phenylpropanolamine—are intended to be taken at minimum intervals of four hours. The maximum total daily intake of the Acetaminophen component is typically restricted to 4000 milligrams (4 grams) in a 24-hour period, a limit established to define proper usage. The combination is designed for intermittent use and is not intended for prolonged, continuous courses of administration.

Administration Details

For most oral forms, the medicine may be consumed with or without food. Liquid formulations, such as the syrup, require precise measurement using a calibrated device to ensure accurate unit delivery. Pediatric use (children under 12 years) is determined by body weight or age and must adhere to specific instructions provided on the official product label. If a scheduled dose is not taken, it should be administered when remembered, provided the minimum four-hour interval is preserved.

Recent Clinical Evidence

Sinustat: Recent Clinical Evidence

Acute and Chronic Symptom Management

Research has explored the study drug's role in the investigation of both short-term and long-term symptom profiles associated with common cold and flu-like illness. Sinustat is typically a multi-component formulation, and studies generally assess the combination of ingredients on multiple symptoms simultaneously.

Acute Symptom Trials

Randomized, double-blind, placebo-controlled trials have been conducted in adults with acute upper respiratory tract symptoms, including nasal congestion, pain, and fever. The primary endpoint in these trials was the measurement of change in symptom intensity over a short period, typically 4 to 24 hours. Studies investigated the effects on acute pain and congestion, particularly in the immediate post-treatment phase.

Specialized Conditions and Administration

Adverse Event Profile

Safety monitoring is a key component of all clinical research. Various studies collected data on how participants experienced the drug and its adverse event profile. This monitoring included detailed records of discontinuations due to adverse events. Research has also explored the adverse event profile in specific populations, such as older adults and patients with mild-to-moderate renal impairment, comparing observed side effects across these groups.

  • Study protocols evaluated the impact of certain administration conditions on absorption.
  • Research has investigated whether a change in chronic pain levels is seen over several months in some participants, but evidence remains limited on long-term use.

Key Studies & References

  1. Pharmacokinetics and Dose Adjustments of Non-Prescription Medications in Renal Impairment: A Comprehensive Review

Frequently Asked Questions (FAQ)

Common questions about Sinustat (FAQ)

Q: How quickly does Sinustat start to work after I take it?

A: Official documents describe that the decongestant component, Phenylpropanolamine, typically reaches its highest concentration in the bloodstream approximately 1 to 2 hours after administration. The drug is designed to have an intended duration of effect that aligns with the recommended dosing interval of 4 to 6 hours. Individual experiences regarding the onset of effect may vary.


Q: What happens if I miss a dose of Sinustat?

A: According to the official product instructions, if a dose is missed, product instructions describe taking the dose when it is remembered. However, it is essential that the minimum required time interval of at least four hours between any two doses is preserved.


Q: Is Sinustat safe to take while drinking coffee or tea?

A: Official information advises caution when taking Sinustat with other sympathomimetic agents. Because the Phenylpropanolamine component is a sympathomimetic (a drug that stimulates the sympathetic nervous system), co-administration may potentially result in additive sympathomimetic effects. This combination relates to effects such as heart rate or blood pressure.


Q: Does Sinustat have any known interactions with alcohol?

A: Yes, regulatory documents contain explicit warnings regarding the combination of Sinustat with chronic, excessive alcohol consumption. This combination is classified as a risk for severe liver damage due to the acetaminophen component of the drug. The regulatory documents note the potential for harm associated with concurrent use.


Q: What is the expected duration of effect after one dose of Sinustat?

A: The recommended interval for taking subsequent doses of Sinustat is every 4 to 6 hours. This dosing schedule is generally associated with the intended duration of the drug's therapeutic action for symptom relief.


Q: Is it safe to drive after taking Sinustat?

A: Official documentation notes that side effects such as dizziness, giddiness, and tremors have been reported during use. For this reason, official safety information states that caution is necessary when performing activities that require alertness, such as driving or operating machinery while using Sinustat.


Q: Can I stop taking Sinustat suddenly?

A: Sinustat is officially restricted to short-term, intermittent use for acute symptoms. The product labeling does not describe a need for a gradual dose reduction or tapering schedule when discontinuing the medicine after a short course of treatment.


Q: Is it normal to have a slight headache when starting Sinustat?

A: Headache is an adverse effect that has been listed in official product information, which monitors how participants experience the medication. It is listed as a nervous system effect that has been reported in association with the drug's components.


Q: Is Sinustat a type of antibiotic?

A: No, Sinustat is officially classified as an Upper Respiratory Combination medication. It is composed of a pain/fever reducer and a decongestant, and it is not documented in regulatory sources as having antibacterial properties.


Q: Can Sinustat be used for conditions other than what's on the label?

A: Regulatory agencies authorize the use of Sinustat only for the specific indications that are officially listed in the product's official labeling. The use of the drug for conditions not specifically listed in the labeling is outside the scope of its authorized regulatory approval.


Q: What's the difference between Sinustat and regular pain relievers?

A: Official documents indicate that Sinustat is a combination product. Unlike regular single-ingredient pain relievers, Sinustat contains both a pain and fever reducer (Acetaminophen) and a decongestant (Phenylpropanolamine) to address multiple symptoms simultaneously.


Q: Can I take Sinustat with my vitamins and minerals?

A: While specific warnings against common vitamins are usually absent from official labeling, regulatory information generally advises disclosing all products used, including vitamins and supplements, to a healthcare provider, consistent with general regulatory guidance on disclosing all products used.


Q: Is Sinustat addictive or habit-forming?

A: According to official documentation, Sinustat is not classified as a controlled substance. It is not typically documented in regulatory records as being associated with addiction or habit-forming potential.


Q: Why is Sinustat sometimes prescribed in combination with other drugs?

A: The official regulatory indication is based on the components working through different pathways to relieve multiple symptoms simultaneously. It is designed to target both central symptoms (pain/fever) and peripheral congestion.


Q: Is Sinustat taken with or without food?

A: The official administration details state that for most oral forms, the medication may be consumed either with or without food. This instruction relates to how food may affect the absorption of the active ingredients.


Q: Is there a generic version of Sinustat available?

A: The existence of generic versions is determined by regulatory bodies like the FDA, which maintains approved drug product lists. The availability of an authorized generic version for a specific branded product can vary by region and time.


Q: Does Sinustat help with swelling?

A: The mechanism of action of the decongestant component (Phenylpropanolamine) is to directly stimulate receptors on blood vessels in the nasal and sinus lining, causing them to constrict. This physiological adjustment reduces blood pooling and can physically reduce the volume of the mucosal tissue.


Q: Is the mechanism of action of Sinustat fully understood by scientists?

A: Yes, the official labeling contains dedicated sections that provide detailed explanations of how both the fever/pain reducer (Acetaminophen) and the decongestant (Phenylpropanolamine) are understood to work within the body at a chemical and physiological level.


Q: What are the signs of an allergic reaction to Sinustat?

A: Regulatory warnings mention the risk of rare but serious hypersensitivity reactions, including life-threatening cutaneous reactions such as Stevens-Johnson Syndrome (SJS). Signs of an allergic reaction may include fever, rash, or blistering of the skin.


Q: Is Sinustat a prescription-only medicine?

A: The regulatory status of the drug determines whether it is classified as a prescription-only medicine (Rx) or an over-the-counter (OTC) medicine. This classification is based on the components and strength, and it may differ between various regulatory jurisdictions.


Q: What if I take Sinustat and feel no different?

A: Clinical trials generally measure the drug's effects as an average response across a large group of people. Official information indicates that individual response to medication can vary, and not every person may perceive the same level of symptomatic difference.


Q: Why did my doctor prescribe Sinustat instead of an over-the-counter medicine?

A: The availability of different strengths and specific components, including the formulation of Phenylpropanolamine, can determine its regulatory classification. In some jurisdictions, certain combinations or strengths of these ingredients are only available through a prescription.


Q: Is Sinustat the same type of medicine as [similar drug name]?

A: The official classification defines Sinustat as an upper respiratory combination product. A medicine is considered the same 'type' if it contains comparable active ingredients or is intended to treat similar symptoms through the same pharmacological classes.


Q: What should I do if a side effect gets worse while on Sinustat?

A: Patient information generally notes that healthcare provider consultation is recommended if any side effects worsen or if new, concerning symptoms develop while taking the medicine. This is consistent with standard regulatory safety statements.


Q: Is Sinustat approved for chronic conditions?

A: The regulatory documentation places strict limitations on its use, restricting Sinustat to short-term, intermittent courses of administration. Therefore, it is not officially approved for the management of chronic conditions.


Q: Why do some people say Sinustat made them feel dizzy?

A: Dizziness is officially listed in the product's regulatory labeling as an adverse reaction that has been reported. This effect is classified under nervous system disorders, which are related to the central nervous system effects of the drug's components.


Q: Is Sinustat considered a 'high-risk' drug by official agencies?

A: Regulatory documents do contain prominent warnings, including a Boxed Warning, that emphasize the risk of serious adverse events such as liver damage and hemorrhagic stroke. This indicates the regulatory importance placed on appropriate use and adherence to dosing limits to minimize risk.


Q: Do researchers still study new uses for Sinustat?

A: Regulatory databases that track clinical trials often contain information about ongoing investigations related to approved drugs or their components. Research is continually conducted to monitor safety and study administration conditions for drugs already on the market.

How should Sinustat be stored and disposed of?

How to Store and Dispose of Sinustat?

This medication must be stored according to official regulatory specifications to maintain its stability and ensure household safety.


Storage Conditions

Sinustat must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container, which must be tightly closed.

Storage Requirement Rule
Temperature Controlled Room Temperature (20 C to 25 C)
Environment Keep in a dry place; protect from excessive humidity.
Child Safety Must be kept out of the reach and sight of children.

Disposal Instructions

Expired or unused Sinustat should not be flushed down the toilet or poured down a drain. The preferred disposal method is a drug take-back program.

If a take-back program is unavailable, the product may be mixed with an undesirable substance (such as used coffee grounds) and sealed in a container before disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinustat found in:

A-Z Index: